Overview: HLA-DRB115 TestIntroduction: The HLA-DRB115 Test tests for HLA-DRB115 allele to assess risk for autoimmune diseases like multiple sclerosis, helping diagnose conditions causing neurological symptoms. Affecting 1 in 1,000 people with multiple sclerosis, this allele poses diagnostic challenges due to genetic variability. Following 2023 National Multiple Sclerosis Society (NMSS) guidelines, it uses PCR for high accuracy, supporting molecular pathology screening. This test is vital for risk assessment, diagnosis, and improving outcomes in neurology.
Other Names: HLA-DRB115 Allele Test, MS Risk Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: HLA typing began in the 1980s with research by Hauser, who linked HLA-DRB115 to multiple sclerosis. PCR advancements in the 2000s by Applied Biosystems improved detection, surpassing earlier serology methods.
Purpose: Detects HLA-DRB115 allele to assess multiple sclerosis risk, guides immunosuppressive therapy, and evaluates patients with neurological symptoms, aiming to manage disease.
Test Parameters: HLA-DRB115 allele presence
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of neurological issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document neurological symptoms. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., paralysis), and sample collection risks.
Procedural Considerations: Uses PCR to detect alleles, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive allele indicates risk, guiding therapy. Early treatment might prevent progression, while negative results may require MRI.
Specialist Consultation: Consult a neurologist for interpretation.
Additional Supporting Tests: MRI, CSF analysis, or autoimmune panel to confirm diagnosis.
Test Limitations: Indicates risk only; correlation with symptoms needed. False negatives possible with other alleles.
References: NMSS Guidelines, 2023; Neurology, Hauser SL, 2022.
